Literature DB >> 2653511

Busulfan (Bu) and cyclophosphamide (Cy) for marrow transplantation.

G W Santos1.   

Abstract

Bu and Cy is a bone marrow transplant preparative regimen that is effective for ANLL and certain genetic diseases. It has shown promise in CML. Its effectiveness in ALL and lymphomas remains to be explored. The substitution of Bu for TBI in marrow transplant regimens would seem to have a number of practical and theoretical advantages.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2653511

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  12 in total

1.  Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience.

Authors:  J Gayoso; P Balsalobre; M J Pascual; C Castilla-Llorente; L López-Corral; M Kwon; D Serrano; J L Piñana; P Herrera; C Ferrá; C Pascual; I Heras; P Montesinos; A Zabalza; L Bento; A Figuera; I Buño; J L Díez-Martín
Journal:  Bone Marrow Transplant       Date:  2016-05-09       Impact factor: 5.483

Review 2.  The role of busulfan in bone marrow transplantation.

Authors:  M Hassan
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

3.  Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation.

Authors:  Eucario Leon-Rodriguez; Monica M Rivera-Franco
Journal:  Int J Hematol       Date:  2016-10-08       Impact factor: 2.490

4.  Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Arnon Nagler; Myriam Labopin; Norbert-Claude Gorin; Felicetto Ferrara; Miguel A Sanz; Depei Wu; Antonio Torres Gomez; Simona Lapusan; Giuseppe Irrera; Jose E Guimaraes; Aida Botelho Sousa; Angelo M Carella; Norbert Vey; William Arcese; Avichai Shimoni; Raanan Berger; Vanderson Rocha; Mohamad Mohty
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

5.  Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.

Authors:  M Hassan; G Oberg; M Björkholm; I Wallin; M Lindgren
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 6.  Busulfan in hematopoietic stem cell transplantation.

Authors:  Stefan O Ciurea; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2009-02-12       Impact factor: 5.742

7.  Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase.

Authors:  Sulaiman Al-Hashmi; Piet J M Boels; Fahad Zadjali; Behnam Sadeghi; Johan Sällström; Kjell Hultenby; Zuzana Hassan; Anders Arner; Moustapha Hassan
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

8.  Treatment of oral mucositis in hematologic patients undergoing autologous or allogeneic transplantation of peripheral blood stem cells: a prospective, randomized study with a mouthwash containing camelia sinensis leaf extract.

Authors:  Giovanni Carulli; Melania Rocco; Alessia Panichi; Chiara Feira Chios; Ester Ciurli; Chiara Mannucci; Elisabetta Sordi; Francesco Caracciolo; Federico Papineschi; Edoardo Benedetti; Mario Petrini
Journal:  Hematol Rep       Date:  2013-04-04

Review 9.  Epileptic Seizures After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Zhuo Wang; Munan Zhao; Sujun Gao
Journal:  Front Neurol       Date:  2021-07-16       Impact factor: 4.003

10.  A rapid & sensitive liquid chromatography- tandem mass spectrometry method for the quantitation of busulfan levels in plasma & application for routine therapeutic monitoring in haematopoietic stem cell transplantation.

Authors:  Salamun Desire; Ezhil Pavai Mohanan; Biju George; Vikram Mathews; Mammen Chandy; Alok Srivastava; Poonkuzhali Balasubramanian
Journal:  Indian J Med Res       Date:  2013-04       Impact factor: 2.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.